Bristol-Myers Squibb

Bristol-Myers Squibb holds the exclusive license to develop, manufacture and commercialize the monoclonal antibody treatment owned by Rockefeller University.

The company is also part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics”.